Y03301 Recombinant Human Noggin

Cat#:Y03301

Species:Human

Size:10μg/50μg/1mg

Purity:≥95%

Endotoxin: ≤10 EU/mg

Online Consultation

Application Details
Data
Related Applications

Application Details

Cat. No.

Y03301

Purity

≥95%, by SDS-PAGE (under reducing (R) & Non-reducing conditions, visualized by Coomassie staining).

Endotoxin

≤10 EU/mg by the LAL method.

Bioactivity

Determined by its abitity to inhibit 5.0 ng/mL of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The ED₅₀ for this effect is 2.0-3.0 ng/mL of Noggin.

Accession

Q13253

Alternative Names

Noggin; NOG

Species

Human

Expression System

CHO

Mol. Weight

23 kDa

Expression Region

Gln28-Cys232

Tag Info

Tag free

Formulation

Lyophilized

Buffer

PBS, 5% Mannitol and 0.01% Tween 80, pH7.4.

Size

10μg/50μg/1mg

Lead Time

Products are in stock, but custom products may require further consultation.

Reconstitution

It is recommended to redissolve in sterile deionized water.

Shipping

The product is shipped with blue ice.

Storage & Stability

36 months at -20°C to -80°C in lyophilized state;

6 months at -20°C to -80°C under sterile conditions after reconstitution;

7-10 days at 2°C to 8°C under sterile conditions after reconstitution;

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Data

SDS-PAGE

Recombinant Human Noggin (Cat. No. Y03301) SDS-PAGE under reducing (R) & Non-reducing conditions. The gel was stained with Y03301 SDS-PAGE.

Bioactivity

Measured by its ability to inhibit 5.0 ng/mL of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrocenic cells. The bioactivity of Recombinant Human Noggin (Cat. No.Y03301) is equivalent to competitor.

Bioactivity